Accuracy of diabetic retinopathy screening not affected by mydriasis

Article

An investigation published in the Archives of Ophthalmology has indicated that the accuracy of screening for diabetic retinopathy (DR) is affected by the qualifications of retinal photographers but not by mydriasis.

An investigation published in the Archives of Ophthalmology has indicated that the accuracy of screening for diabetic retinopathy (DR) is affected by the qualifications of retinal photographers but not by mydriasis.

The team, led by Dr Peter Bragge of the National Trauma Research Institute, Melbourne, Australia, researched how mydriasis and the medical qualifications of photographers who take retinal photographs influence the screening accuracy for DR.

The researchers analysed studies that measured the sensitivity and specificity of tests designed to detect any DR, sight-threatening DR or macular oedema. The effects of variations in mydriatic status and in the medical qualifications of photographers on sensitivity and specificity were looked at through random-effects logistic regression.

It was found that the only group of tests that were consistent enough for meta analysis was the "any DR" category. In these studies no significant influence to sensitivity or specificity was found when the mydriatic status varied. This was also true for variations in medical qualifications of photographers. However, the specificity of detection of any DR was higher in screening methods using a photographer with specialist medical or eye qualifications.

It was concluded that outreach screening is a successful alternative to on-site specialist examination. The procedure is ideal for screening high-risk diabetic retinopathy patients in rural areas or areas with limited screening facilities. However, the study was confined to the presence or absence of DR and future work should use consistent DR classification schemes.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.